These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17631590)

  • 1. Pharmacodynamic endpoints in primary breast cancer.
    Di Cosimo S; Baselga J
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix21-3. PubMed ID: 17631590
    [No Abstract]   [Full Text] [Related]  

  • 2. [San Antonio Breast Cancer Symposium 2003. New therapeutic prospects in the treatment of early-stage breast cancer].
    Montemurro F
    Tumori; 2004; 90(1):suppl 1-16. PubMed ID: 15143995
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data.
    Khaki AR; Gadi VK; Prasad V
    J Natl Compr Canc Netw; 2019 Dec; 17(12):1456-1458. PubMed ID: 31805524
    [No Abstract]   [Full Text] [Related]  

  • 4. Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007.
    Pegram M; Perez EA; Piccart M; Spector N
    Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S131-41. PubMed ID: 18777952
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictive factors for response to cytotoxic treatment in advanced breast cancer: a review.
    Sjöström J; Blomqvist C
    Acta Oncol; 1996; 35 Suppl 5():84-90. PubMed ID: 9142975
    [No Abstract]   [Full Text] [Related]  

  • 6. Speed SPYing: adaptive clinical trials hit the gas.
    Zipkin M
    Nat Biotechnol; 2019 Sep; 37(9):975-977. PubMed ID: 31485040
    [No Abstract]   [Full Text] [Related]  

  • 7. HER2-positive advanced breast cancer.
    Robert NJ; Favret AM
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):293-302. PubMed ID: 17512450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials referral resource. Clinical trials with paclitaxel in metastatic breast cancer.
    Cheson BD; Abrams JS; Arbuck SG; Phillips PH
    Oncology (Williston Park); 1994 Jan; 8(1):72-3, 76-7. PubMed ID: 7907222
    [No Abstract]   [Full Text] [Related]  

  • 9. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between estrogen-receptor proteins and response to chemotherapy in breast cancer.
    Levine RM; Lippman ME
    Cancer Treat Rep; 1984 Apr; 68(4):573-6. PubMed ID: 6370427
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted Therapies in Older Adults With Breast Cancer: What Do We Know?
    Strulov Shachar S; Hurria A; Muss HB
    J Clin Oncol; 2016 Oct; 34(28):3486-8. PubMed ID: 27432932
    [No Abstract]   [Full Text] [Related]  

  • 12. Trastuzumab (herceptin) for early-stage breast cancer.
    Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Few positives for triple-negative breast cancer.
    Hede K
    J Natl Cancer Inst; 2011 Apr; 103(7):532-3. PubMed ID: 21436063
    [No Abstract]   [Full Text] [Related]  

  • 15. Primary chemotherapy for early breast cancer.
    Ellis PA; Smith IE
    Cancer Treat Rev; 1996 Nov; 22(6):437-50. PubMed ID: 9134004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
    Tuma RS
    J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of chemotherapy in stage I breast cancer.
    Bonadonna G; Valagussa P
    Important Adv Oncol; 1989; ():151-60. PubMed ID: 2651285
    [No Abstract]   [Full Text] [Related]  

  • 18. Emerging targeted therapies for breast cancer.
    Arnedos M; Seidman AD
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):321-40. PubMed ID: 17512452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Checkpoint inhibitors in breast cancer: hype or promise?
    McArthur HL
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806
    [No Abstract]   [Full Text] [Related]  

  • 20. Biological therapy of breast cancer: recent clinical applications.
    Baar J
    Curr Opin Investig Drugs; 2007 Dec; 8(12):987-95. PubMed ID: 18058569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.